Literature DB >> 25450826

Signal persistence and amplification in cancer development and possible, related opportunities for novel therapies.

Shea A Ford1, George Blanck2.   

Abstract

Research in cancer biology has been largely driven by experimental approaches whereby discreet inputs are used to assess discreet outputs, for example, gene-knockouts to assess cancer occurrence. However, cancer hallmarks are only rarely, if ever, exclusively dependent on discreet regulatory processes. Rather, cancer-related regulatory factors affect multiple cancer hallmarks. Thus, novel approaches and paradigms are needed for further advances. Signal pathway persistence and amplification, rather than signal pathway activation resulting from an on/off switch, represent emerging paradigms for cancer research, closely related to developmental regulatory paradigms. In this review, we address both mechanisms and effects of signal pathway persistence and amplification in cancer settings; and address the possibility that hyper-activation of pro-proliferative signal pathways in certain cancer settings could be exploited for therapy.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Apoptosis-effector genes; Cancer hallmarks; Cancer therapy; Hyper-activation of proliferative pathways; Signal amplification; Sustained activation

Mesh:

Year:  2014        PMID: 25450826     DOI: 10.1016/j.bbcan.2014.11.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma.

Authors:  Saif Zaman; Boris I Chobrutskiy; George Blanck
Journal:  Cell Cycle       Date:  2018-11-18       Impact factor: 4.534

2.  Elucidating feed-forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome.

Authors:  Diana A Fisler; Dhiraj Sikaria; John M Yavorski; Yaping N Tu; George Blanck
Journal:  Oncol Lett       Date:  2018-06-12       Impact factor: 2.967

3.  De novo, systemic, deleterious amino acid substitutions are common in large cytoskeleton-related protein coding regions.

Authors:  Rebecca J Stoll; Grace R Thompson; Mohammad D Samy; George Blanck
Journal:  Biomed Rep       Date:  2016-12-08

4.  Impact of SNPs on CpG Islands in the MYC and HRAS oncogenes and in a wide variety of tumor suppressor genes: A multi-cancer approach.

Authors:  Mohammad D Samy; John M Yavorski; James A Mauro; George Blanck
Journal:  Cell Cycle       Date:  2016-06-17       Impact factor: 4.534

5.  Identification of Sets of Cytoskeletal Related and Adhesion-related Coding Region Mutations in the TCGA Melanoma Dataset that Correlate with a Negative Outcome.

Authors:  John M Yavorski; Rebecca J Stoll; Mohammad D Samy; James A Mauro; George Blanck
Journal:  Curr Genomics       Date:  2017-06       Impact factor: 2.236

6.  An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia.

Authors:  Andrea Diviney; Boris I Chobrutskiy; Saif Zaman; George Blanck
Journal:  Cancer Cell Int       Date:  2019-03-27       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.